Human IgG1, IgG3, and IgG3 hinge-truncated mutants show different protection capabilities against meningococci depending on the target antigen and epitope specificity

Clinical and Vaccine Immunology

Volumn 23, Issue 8, 2016, Pages 698-706

  Giuntini, S ^a,d,e   Granoff, D M ^a   Beernink, P T ^a   Ihle, O ^b   Bratlie, D ^b   Michaelsen, T E ^b,c  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d MassBiologics ^*  (United States)

^e UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; EPITOPE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; MENINGOCOCCUS VACCINE; PORIN A; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; PORIN; PORIN PROTEIN, NEISSERIA; RECOMBINANT PROTEIN;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CHIMERA; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HINGE EXON; HINGE REGION; HUMAN; HUMAN CELL; MUTANT; NEISSERIA MENINGITIDIS; OUTER MEMBRANE; PRIORITY JOURNAL; ADULT; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE; SERUM BACTERICIDAL ACTIVITY;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT ACTIVATION; EPITOPES; HUMANS; IMMUNOGLOBULIN G; MICE; NEISSERIA MENINGITIDIS; PORINS; RECOMBINANT PROTEINS;

EID: 84982965914     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00193-16     Document Type: Article

References (60)

1. Frasch CE, Zollinger WD, Poolman JT. 1985. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504-510. http://dx.doi.org/10.1093/clinids/7.4.504.
2. Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, Achtman M. 1992. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 60:5267-5282.
3. Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. 1993. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 167:1320-1329. http://dx.doi.org/10.1093/infdis/167.6.1320.
4. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, Borsboom D, van der Ark A, van Straaten I, Roholl P, Kuipers B, Poolman J. 1996. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008. http://dx.doi.org/10.1016/0264-410X (96) 00020-5.
5. Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM. 1998. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 66:4755-4761.
6. Rosenqvist E, Hoiby EA, Wedege E, Bryn K, Kolberg J, Klem A, Ronnild E, Bjune G, Nokleby H. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63:4642-4652.
7. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outermembrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
8. van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59:2963-2971.
9. Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7:325-328. http://dx.doi.org/10.1016/0264-410X (89) 90194-1.
10. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to crossreactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129. http://dx.doi.org/10.1016/j.vaccine.2009.12.027.
11. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. 2011. Meningococcal factorHbinding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 5:e1302. http://dx.doi.org/10.1371/journal.pntd.0001302.
12. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197:1053-1061. http://dx.doi.org/10.1086/528994.
13. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factorHand enhances serum resistance. J Immunol 177:501-510. http://dx.doi.org/10.4049/jimmunol.177.1.501.
14. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly crossreactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Sci Rep 2:341. http://dx.doi.org/10.1038/srep00341.
15. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172:5606-5615. http://dx.doi.org/10.4049/jimmunol.172.9.5606.
16. Pajon R, Fergus AM, Granoff DM. 2013. Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa. PLoS One 8:e66536. http://dx.doi.org/10.1371/journal.pone.0066536.
17. Burton DR, Gregory L, Jefferis R. 1986. Aspects of the molecular structure of IgG subclasses. Monogr Allergy 19:7-35.
18. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351-1361. http://dx.doi.org/10.1084/jem.166.5.1351.
19. Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520. http://dx.doi.org/10.3389/fimmu.2014.00520.
20. Michaelsen TE, Garred P, Aase A. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 21:11-16. http://dx.doi.org/10.1002/eji.1830210103.
21. Garred P, Michaelsen TE, Aase A. 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 30:379-382. http://dx.doi.org/10.1111/j.1365-3083.1989.tb01225.x.
22. Giuntini S, Reason DC, Granoff DM. 2012. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factorH binding protein. Infect Immun 80:187-194. http://dx.doi.org/10.1128/IAI.05956-11.
23. Michaelsen TE, Ihle O, Beckstrom KJ, Herstad TK, Kolberg J, Hoiby EA, Aase A. 2003. Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes. Infect Immun 71:5714-5723. http://dx.doi.org/10.1128/IAI.71.10.5714-5723.2003.
24. Michaelsen TE, Frangione B, Franklin EC. 1977. Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. J Biol Chem 252:883-889.
25. Huck S, Fort P, Crawford DH, Lefranc MP, Lefranc G. 1986. Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes. Nucleic Acids Res 14:1779-1789. http://dx.doi.org/10.1093/nar/14.4.1779.
26. Roux KH, Strelets L, Michaelsen TE. 1997. Flexibility of human IgG subclasses. J Immunol 159:3372-3382.
27. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 76:4232-4240. http://dx.doi.org/10.1128/IAI.00367-08.
28. Giuliani MM, Santini L, Brunelli B, Biolchi A, Arico B, Di MF, Cartocci E, Comanducci M, Masignani V, Lozzi L, Savino S, Scarselli M, Rappuoli R, Pizza M. 2005. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73:1151-1160. http://dx.doi.org/10.1128/IAI.73.2.1151-1160.2005.
29. Scarselli M, Cantini F, Santini L, Veggi D, Dragonetti S, Donati C, Savino S, Giuliani MM, Comanducci M, Di Marcello F, Romagnoli G, Pizza M, Banci L, Rappuoli R. 2009. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol 386:97-108. http://dx.doi.org/10.1016/j.jmb.2008.12.005.
30. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol 46:1647-1653. http://dx.doi.org/10.1016/j.molimm.2009.02.021.
31. Wang J, Jarvis GA, Achtman M, Rosenqvist E, Michaelsen TE, Aase A, Griffiss JM. 2000. Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect Immun 68:1871-1878. http://dx.doi.org/10.1128/IAI.68.4.1871-1878.2000.
32. van den Elsen J, Vandeputte-Rutten L, Kroon J, Gros P. 1999. Bactericidal antibody recognition of meningococcal PorA by induced fit. Comparison of liganded and unliganded Fab structures. J Biol Chem 274:1495-1501.
33. Ihle O, Beckstrom KJ, Michaelsen TE. 2003. Cloning, sequencing and expression of immunoglobulin variable regions of murine monoclonal antibodies specific for the P1.7 and P1.16 PorA protein loops of Neisseria meningitidis. Scand J Immunol 57:453-462. http://dx.doi.org/10.1046/j.1365-3083.2003.01255.x.
34. Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. 1997. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 204:77-87. http://dx.doi.org/10.1016/S0022-1759 (97) 00034-3.
35. Pagotto FJ, Salimnia H, Totten PA, Dillon JR. 2000. Stable shuttle vectors for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single origin of replication. Gene 244:13-19.
36. Koeberling O, Giuntini S, Seubert A, Granoff DM. 2009. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 16:156-162. http://dx.doi.org/10.1128/CVI.00403-08.
37. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186:3606-3614. http://dx.doi.org/10.4049/jimmunol.1003470.
38. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79:3751-3759. http://dx.doi.org/10.1128/IAI.05182-11.
39. Hari SB, Lau H, Razinkov VI, Chen S, Latypov RF. 2010. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry 49:9328-9338. http://dx.doi.org/10.1021/bi100841u.
40. Beernink PT, Shaughnessy J, Ram S, Granoff DM. 2010. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clin Vaccine Immunol 17:1074-1078. http://dx.doi.org/10.1128/CVI.00103-10.
41. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie JE, III, Moran EE, Brandt BL, Ionin B, Marques R, Wu M, Chen P, Stoddard MB, Keiser PB. 2010. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28:5057-5067. http://dx.doi.org/10.1016/j.vaccine.2010.05.006.
42. Carulli G, Ottaviano V, Cannizzo E, Giuntini S, Manetti C, Ciancia EM, Azzara A. 2012. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Ter 163:387-392.
43. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(Suppl 2):B87-B97. http://dx.doi.org/10.1016/j.vaccine.2012.01.033.
44. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69:1568-1573. http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001.
45. Frasch CE, Borrow R, Donnelly J. 2009. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112-B116. http://dx.doi.org/10.1016/j.vaccine.2009.04.065.
46. Costa I, Pajon R, Granoff DM. 2014. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio 5:e01625-14. http://dx.doi.org/10.1128/mBio.01625-14.
47. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. 1998. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol 161:4083-4090.
48. Tan LK, Shopes RJ, Oi VT, Morrison SL. 1990. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A 87:162-166. http://dx.doi.org/10.1073/pnas.87.1.162.
49. Michaelsen TE, Aase A, Norderhaug L, Sandlie I. 1992. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol Immunol 29:319-326. http://dx.doi.org/10.1016/0161-5890 (92) 90018-S.
50. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6:e1001027. http://dx.doi.org/10.1371/journal.ppat.1001027.
51. Giuntini S, Pajon R, Ram S, Granoff DM. 2015. Binding of complement factorHto PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun 83:1536-1545. http://dx.doi.org/10.1128/IAI.02984-14.
52. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4:e00339-13. http://dx.doi.org/10.1128/mBio.00339-13.
53. Rosner T, Lohse S, Peipp M, Valerius T, Derer S. 2014. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. J Immunol 193:1485-1495. http://dx.doi.org/10.4049/jimmunol.1400329.
54. Olafsen T, Munthe Lund CK, Bruland OS, Sandlie I, Michaelsen TE. 1999. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunol Immunother 48:411-418. http://dx.doi.org/10.1007/s002620050594.
55. Jefferis R. 2007. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7:1401-1413. http://dx.doi.org/10.1517/14712598.7.9.1401.
56. Vestrheim AC, Moen A, Egge-Jacobsen W, Bratlie DB, Michaelsen TE. 2013. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines. Scand J Immunol 77:419-428. http://dx.doi.org/10.1111/sji.12046.
57. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O. 2009. Structural difference in the complement activation site of human IgG1 and IgG3. Scand J Immunol 70:553-564. http://dx.doi.org/10.1111/j.1365-3083.2009.02338.x.
58. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6:228ra239. http://dx.doi.org/10.1126/scitranslmed.3007730.
59. Naess LM, Aarvak T, Aase A, Oftung F, Hoiby EA, Sandin R, Michaelsen TE. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764. http://dx.doi.org/10.1016/S0264-410X (98) 00259-X.
60. Beale D, Feinstein A. 1976. Structure and function of the constant regions of immunoglobulins. Q Rev Biophys 9:135-180. http://dx.doi.org/10.1017/S0033583500002390.